Stephen Benoit – President & Chief Executive Officer. Stephen Benoit is an executive with experience in several start-ups in the biotechnology, pharmaceutical, nutrigenetics, consumer packaged goods, and financial services industries. Mr. Benoit’s background includes mergers and acquisitions, strategic planning, new business development, international business development, international operations management, and finance. Most recently, Mr. Benoit served as Vice President Sales & Marketing for a nutrigenetic testing start-up company. Prior to joining NanoMed, he was a Corporate Officer of a Fortune 250 company, responsible for leading a $250 million division. Mr. Benoit has also served as Vice President Marketing and Sales for an antimicrobial peptide manufacturer, and Vice President Marketing for a leading biotechnology company. He began his career at Bank of America.
Mr. Benoit has served as a consultant to a number of companies ranging from start-ups to Fortune 100 companies. He has been an invited guest lecturer at the Darden School of Business, University of Virginia; the Wharton School of Business, University of Pennsylvania; Case Western Reserve University Weatherhead School of Management; Western Michigan University; and the Graduate School of Management, University of California Davis. Mr. Benoit received an MBA in Finance from Loyola Marymount University and is a member of the Alpha Sigma Nu, the national Jesuit academic honor society.
Harry C. Ledebur, Jr., Ph.D. – Vice President Research & Development, Chief Scientific Officer. Dr. Ledebur is an executive with extensive experience in preclinical discovery research, product development and business development within the biotechnology sector and large pharmaceutical industry. His background also includes successful mergers and acquisitions, early stage financings and the establishment of a profitable service business in the biopharmaceutical sector. Prior to joining NanoMed, Dr. Ledebur was Vice President, Operations and Scientific Affairs at Chromos Molecular Systems. Previously, he was with Caprion Pharmaceuticals Inc. where he served as Vice President of Discovery Programs and Vice President of Research & Development. Dr. Ledebur also served as Program Head of the Antigen Presenting Cell Program at Valentis, Inc. (formerly GeneMedicine, Inc.) where he focused on the development of DNA-based vaccines for cancer and infectious disease. He began his career at Boehringer Ingelheim Pharmaceuticals Inc. as a Research Fellow. Dr. Ledebur received his Ph.D. in Molecular & Cell Biology from Pennsylvania State University and his B.Sc. in Biochemistry from The Ohio State University.
Gabriel Leung – Director. Mr Leung is President, Oncology, at OSI Pharmaceuticals, a leading biotechnology company and maker of Tarceva® with responsibilities for the oncology research, development, and commercial operations. Before joining OSI, Mr. Leung was Group Vice President, Global Prescription Business at Pharmacia, where he served on the CEO’s Operating Committee and headed up the company’s Oncology Franchise with business and medical affairs operations in over 80 countries. Mr. Leung also oversaw all the oncology research and development projects and portfolio strategies as the co-chair of Pharmacia’s Oncology Development Committee. During his 4-year tenure at Pharmacia, which ended with the acquisition by Pfizer, Mr. Leung doubled the size of the oncology business to $1.3 billion in revenues, building it into one of the then largest oncology therapeutic companies in the world. He orchestrated two new product launches and helped build one of the strongest oncology pipelines in the industry through acquisition and in-licensing. Mr. Leung began his career in the pharmaceutical industry at Eastman Pharmaceuticals/Sterling Drug Inc., and then had a distinguished career at Bristol-Myers Squibb working on blockbuster products including Pravachol®, Taxol®, and Paraplatin®.
Mr. Leung is a pharmacist, trained at the University of Texas at Austin where he earned his pharmacy degree with High Honors. Following some years of practice in the hospital environment, Mr. Leung earned his M.S. degree at the University of Wisconsin-Madison with concentration in pharmaceutical marketing. Mr. Leung is a member of the National Cancer Institute Clinical Trial Advisory Committee and is the founding chairman of the Life Sciences Consortium, an initiative of the CEO Roundtable on Cancer. He is also an active member and a member of the Nominating Committee of C-Change (www.cchangetogether.org), a national initiative chaired by former President George Bush and Mrs. Barbara Bush with the goal of eliminating cancer as a major public health problem at the earliest possible time.
Russell J. Mumper, Ph.D. – Co-Founder and Director. Dr. Mumper is the John A. McNeill Distinguished Professor in the Molecular Pharmaceutics Division in the School of Pharmacy, and the first Director of the Center for Nanotechnology in Drug Delivery at The University of North Carolina at Chapel Hill.
From 1999-2007, Dr. Mumper was a faculty member in the Department of Pharmaceutical Sciences in the College of Pharmacy at the University of Kentucky. He served as Vice Chair of the Department from 1994 to 1997. Also, from 1999-2006, Dr. Mumper was the Associate Director of the Center for Pharmaceutical Science & Technology (CPST). Prior to becoming a for-profit company in 2007, the CPST was a unique university-based fully-integrated FDA-registered GMP pharmaceutical manufacturing facility. Dr. Mumper led the CPST’s efforts to complete full product development resulting in the successful submission of seven different INDs and commencement of human clinical trials with both industrial and university partners.
After completing a post-doctoral fellowship in the Center for Bioengineering at the University of Washington in 1992, Dr. Mumper held various product development positions in the pharmaceutical/biotech industry working for Burroughs-Wellcome Co. in North Carolina and GeneMedicine, Inc. and Virotex Corporation, both in The Woodlands, Texas. Since returning to academia in 1999, Dr. Mumper has received over $6.3 million in research grants/contracts as Principal Investigator (and over $8.3 million total). Dr. Mumper has more than 190 scientific publications/abstracts and 35 patents or patents pending. Dr. Mumper serves on the Editorial Board of three pharmaceutical journals and is an ad-hoc member of several different scientific review panels for the National Institutes of Health.
In 2006, he received the AAPS Lipid-based Drug Delivery Award sponsored by Gattefossé Corporation and the American Association of Pharmaceutical Scientists (AAPS). In 2007, Dr. Mumper was recognized by the University of Kentucky (UK) Alumni Association as one of six “Great Teachers” at UK. This award is the oldest, continuously given award for teaching on UK’s campus.
Dr. Mumper has co-founded three companies; NanoMed Pharmaceuticals Inc. based in Kalamazoo, Michigan, and Four Tigers LLC and Berryceuticals LLC both based in Paris and Lexington, Kentukcy. These companies were founded on technology developed in his laboratories.
Douglas R. Morton, Jr., Ph.D. – Director. Dr. Morton is a principal of PharmMor Consulting, LLC. Dr. Morton has spent his entire career in the pharmaceutical industry. He graduated magna cum laude from Kenyon College in 1967 with an A.B. and High Honors in Chemistry. Dr. Morton was awarded a Ph.D. in Organic Chemistry in 1971 by Columbia University and completed postdoctoral studies in that field at Stanford University before joining the Upjohn Company as a research scientist in 1973. He remained with the surviving entity through Upjohn’s merger with Pharmacia AB (in 1996), the consolidation of Pharmacia & Upjohn with Monsanto (in 2000), and, recently, Pharmacia’s merger with Pfizer (2003) serving in a series of increasingly significant discovery research management positions. At the time of the Pfizer merger, Dr. Morton was Group Vice President, Technology Acquisitions & Operations for Discovery Research in Pharmacia Corporation. In this position, he was responsible for technology He is a published scientist and prolific inventor who has authored or co-authored 45 peer-reviewed scientific publications and holds 43 U.S. patents.
Dr. Morton has served on the Board of Directors of TissueInformatics, Inc. from May 2003 until the closing of Paradigm Genetics’ acquisition of the company in 2004. Dr. Morton is currently a member of the Board of Directors of Icoria, Inc. (formerly Paradigm Genetics, Inc.) and has served as a member of the Scientific Advisory Board of Celltech R&D of Slough, UK and as a member of the Industrial Advisory Board of Cleveland Clinic Foundation Innovations.
Patrick G. Morand – Director. Patrick G. Morand is Managing Director of the SWMF Life Science Fund, headquartered in Kalamazoo, Michigan. Prior to joining the Fund, Mr. Morand was Executive in Residence of the Pittsburgh Life Sciences Greenhouse (PLSG), a Public/Private investor in regional life sciences companies. In his role, he provided executive support to founders, investors and executives of promising regional life sciences start-up and development stage companies. At PLSG, Mr. Morand grew his personal portfolio from 14 to 65 companies (diagnostics, therapeutics, medical devices, services), representing $100M of investment and 121 employees.
Prior to PLSG, Mr. Morand was a three-time CEO in the biologics industry, Vice President of Commercial Operations for Genesis Therapeutics (an Aventis Behring spinout company) and Executive Vice President of Sequitor Medical Technologies, a startup company founded and funded by former Elan Pharmaceutical executives.